Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Publishing timestamp: 2025-02-21 13:48:03
Summary
Bluebird Bio is selling itself to private equity firms Carlyle and SK Capital for about $30 million, marking the end of its fall from one of the buzziest biotech firms. The company's gene therapies have faced setbacks and financial struggles, leading to the sale. Despite the transformative results seen in patients, the entire gene therapy field is facing tough questions about the viability of these treatments as successful businesses.
Sentiment: NEGATIVE
Keywords: health care industry, vertex pharmaceuticals inc, bluebird bio inc, carlyle group inc, business, business news, pfizer inc,